AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 million upfront to form a new drug discovery pact with Gedeon Richter.

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

An investigation is underway into the "very concerning" leak of classified U.S. intelligence documents detailing Israel’s plans for a retaliatory strike on Iran, House Speaker Mike Johnson ...

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...

The United States has warned Israel it may stop supplying the country with weapons unless the humanitarian situation in Gaza improves. This is not the first time Israel’s major ally has ...

WASHINGTON – Israel’s military said early Saturday it had completed a series of retaliatory airstrikes against Iran in response to an Iranian missile attack, a move that could push the Middle ...

Since Israel and Hamas went to war, reporters and editors at The New York Times have closely covered the conflict. Our coverage includes the Hamas-led attack on Israel, the plight of hostages ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct. 15th. While investors will wait to hear about quarterly earnings on ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide.

AbbVie (NYSE:ABBV) will report third-quarter results next week and I expect to see a continuation of trends from the first half of the year with top and bottom-line beats and an improved full-year ...

Wall Street expects a year-over-year decline in earnings on higher revenues when AbbVie (ABBV) reports results for the quarter ended September 2024. While this widely-known consensus outlook is ...